Marcin Czech

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1096983/publications.pdf

Version: 2024-02-01

1040056 940533 32 314 9 16 citations h-index g-index papers 32 32 32 477 citing authors all docs docs citations times ranked

#	Article	IF	CITATIONS
1	Impact of COVID-19 Pandemic on the Use of Antidepressant and Antianxiety Pharmaceuticals as Well as Sick Leave in Poland. International Journal of Environmental Research and Public Health, 2022, 19, 2135.	2.6	5
2	Relationship between age and in-hospital mortality during 15,345,025 non-surgical hospitalizations. Archives of Medical Science, 2021, 17, 40-46.	0.9	3
3	Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries. Frontiers in Pharmacology, 2019, 10, 487.	3.5	22
4	Prevalence of diabetes in Poland: a combined analysis of national databases. Diabetic Medicine, 2019, 36, 1209-1216.	2.3	18
5	Real-World Evidence of Patient Outcome Following Treatment of Advanced Gastrointestinal Stromal Tumor (GIST) with Imatinib, Sunitinib, and Sorafenib in Publicly Funded Health Care in Poland. Medical Science Monitor, 2019, 25, 3846-3853.	1.1	10
6	A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries. Frontiers in Public Health, 2019, 7, 416.	2.7	61
7	OVERVIEW OF REGULATORY INITIATIVES IN THE EUROPEAN UNION TO STIMULATE RESEARCH AND ACCELERATE ACCESS TO ORPHAN DRUGS AND OTHER HIGH MEDICAL NEED PRODUCTS. Acta Poloniae Pharmaceutica, 2019, 76, 3-17.	0.1	0
8	APPLICABILITY OF THE EVIDEM MULTI-CRITERIA DECISION ANALYSIS FRAMEWORK FOR ORPHAN DRUGS – RESULTS FROM A STUDY IN 7 EURASIAN COUNTRIES Acta Poloniae Pharmaceutica, 2019, 76, 581-598.	0.1	1
9	Chronic heart failure management in primary healthcare in Poland: Results of a nationwide cross-sectional study. European Journal of General Practice, 2018, 24, 1-8.	2.0	6
10	Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugsâ€"a Systematic Literature Review. Next Steps in Methodology Development?. Frontiers in Public Health, 2018, 6, 287.	2.7	38
11	Bridging East with West of Europe – a comparison of orphan drugs policies in Poland, Russia and the Netherlands. Acta Poloniae Pharmaceutica, 2018, 75, 1409-1422.	0.1	2
12	Treatment persistence in the use of basal insulins in Poland and Germany. International Journal of Clinical Pharmacology and Therapeutics, 2017, 55, 119-125.	0.6	4
13	Regional differences in insulin therapy regimens in five European countries. International Journal of Clinical Pharmacology and Therapeutics, 2017, 55, 403-408.	0.6	7
14	Quality of care of hospitalised patients with heart failure in Poland in 2013: results of the second nationwide survey. Kardiologia Polska, 2017, 75, 527-534.	0.6	9
15	Koordynowana opieka w onkologii. , 2017, 15, 146-158.	0.2	1
16	Cost of severe hypoglycaemia in nine European countries. Journal of Medical Economics, 2016, 19, 973-982.	2.1	21
17	Patient's age rather than severity of the arrhythmia influences the cost of medical treatment of atrioventricular nodal or atrioventricular reciprocating tachycardia. Journal of Interventional Cardiac Electrophysiology, 2016, 47, 197-202.	1.3	3
18	Inâ€Hospital Mortality in a 4‥ear Cohort Study of 3,093,254 Operations in Seniors. World Journal of Surgery, 2016, 40, 1068-1074.	1.6	7

#	Article	IF	CITATIONS
19	Drug-related risk of severe hypoglycaemia in observational studies: a systematic review and meta-analysis. BMC Endocrine Disorders, 2015, 15, 57.	2.2	6
20	Cost of hospitalizations due to microvascular and macrovascular complications in type 1 and type 2 diabetic patients in Bulgaria. Biotechnology and Biotechnological Equipment, 2015, 29, 805-813.	1.3	9
21	Economic resources consumption structure in severe hypoglycemia episodes: a systematic review and meta-analysis. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 813-822.	1.4	7
22	Comparative Analysis of the Cost of Insulin Treated Patients in Bulgaria. Biotechnology and Biotechnological Equipment, 2013, 27, 3748-3752.	1.3	6
23	Costs of Medically Attended Acute Gastrointestinal Infections: The Polish Prospective Healthcare Utilization Survey. Value in Health Regional Issues, 2013, 2, 210-217.	1.2	2
24	Mortality after surgery in Europe. Lancet, The, 2013, 381, 369-370.	13.7	8
25	Antibacterial prescriptions for acute gastrointestinal infections: uncovering the iceberg. Epidemiology and Infection, 2013, 141, 859-867.	2.1	12
26	The costs of heart failure in Poland from the public payer's perspective. Polish programme assessing diagnostic procedures, treatment and costs in patients with heart failure in randomly selected outpatient clinics and hospitals at different levels of car. Kardiologia Polska, 2013, 71, 224-232.	0.6	37
27	Measuring quality, equity, outcomes and efficiency in pharmaceutical care as a part of managed care. International Journal of Integrated Care, 2013, 13, .	0.2	O
28	Availability and quality of data on pharmaceutical benefit financing components of health care system in United States, United Kingdom, Denmark, Germany, Italy and Poland. International Journal of Integrated Care, 2013, 13, .	0.2	0
29	Cost-Effectiveness of Biphasic Insulin Aspart 30 VS. Human Premix Insulin in Type 2 Diabetes from the Payer's Perspective in Bulgaria. Biotechnology and Biotechnological Equipment, 2012, 26, 2937-2944.	1.3	4
30	HEALTH TECHNOLOGY ASSESSMENT – IS IT THE WAY TO SEARCH FOR COST – EFFECTIVE MEDICINES IN CENTRAL AND EASTERN EUROPE?. Economics and Sociology, 2011, 4, 119-129.	2.3	0
31	Access to selected diagnostic procedures in the management of heart failure patients in Poland - POLKARD 2005. Kardiologia Polska, 2010, 68, 265-72.	0.6	3
32	Pharmacoeconomic evaluation and healthcare management in Poland. Human Factors and Ergonomics in Manufacturing, 2005, 15, 99-108.	2.7	2